Sort
10,766 grants matching “checkpoint inhibitor”
Targeting MerTK as an immunotherapeutic strategy in acute myeloid leukemia
$175,285Alisa Lee Sherick · University Of Colorado Denver · K08 · FY2018 · CA
Exploring immune surveillance in isocitrate dehydrogenase mutant cholangiocarcinoma
$175,268Supriya K Saha · Fred Hutchinson Cancer Research Center · R21 · FY2019 · CA
Immuno-Phenotyping Core
$175,267Young J. Kim · Vanderbilt University Medical Center · P50 · FY2020 · CA
Full Project 1: Understanding and Targeting of Convergent Immunosuppressive Pathways and Molecular Signaling in HPV-Positive and HPV-Negative Penile Cancer
$174,925Magaly Martinez-Ferrer · University Of Puerto Rico Med Sciences · U54 · FY2021 · CA
BUBR1 in the Spindle Checkpoint and Tumor Suppression
$174,504New York Medical College · R01 · FY2005 · CA
A novel gene-based immunotherapy inducing melanoma destruction
$174,151Katja Michael · University Of Texas El Paso · R21 · FY2024 · CA
PIK3CA signaling and pancreatic cancer
$174,108Richard Z Lin · State University New York Stony Brook · R21 · FY2024 · CA
Inhibition of Stromal-Derived DKK3 to Enhance the Response of Pancreatic Cancer to Immunotherapy
$174,000Rosa F. Hwang · University Of Tx Md Anderson Can Ctr · R21 · FY2018 · CA
Targeting Tankyrases to Mitigate Immunosuppression and Enhance Cancer Immunotherapy
$174,000Steven Hsesheng Lin · University Of Tx Md Anderson Can Ctr · R21 · FY2020 · CA
Immuno-Phenotyping Core
$173,912Young J. Kim · Vanderbilt University Medical Center · P50 · FY2022 · CA
Immuno-Phenotyping Core
$173,912Young J. Kim · Vanderbilt University Medical Center · P50 · FY2023 · CA
Immuno-Phenotyping Core
$173,910Young J. Kim · Vanderbilt University Medical Center · P50 · FY2019 · CA
Role of probiotic Lactobacillus reuteri in orchestrating systemic anti-tumor immunity
$173,867Marlies Meisel · University Of Pittsburgh At Pittsburgh · R21 · FY2022 · CA
Role of the Acetyltransferase p300 in Cellular Responses
$173,857Georgetown University · R01 · FY2003 · CA
A micro-dissection platform for generating uniform-sized patient-derived tumor organoids (PDOs) for personalized cancer therapy
$173,846Sindy Kam-Yan Tang · Stanford University · R21 · FY2024 · CA
Dissecting temporal and spatial dynamics of immunotherapy resistance
$173,772Daniel Faden · Massachusetts Eye And Ear Infirmary · K23 · FY2024 · DE
Dissecting temporal and spatial dynamics of immunotherapy resistance
$173,772Daniel Faden · Massachusetts Eye And Ear Infirmary · K23 · FY2025 · DE
Dissecting temporal and spatial dynamics of immunotherapy resistance
$173,772Daniel Faden · Massachusetts Eye And Ear Infirmary · K23 · FY2021 · DE
Dissecting temporal and spatial dynamics of immunotherapy resistance
$173,772Daniel Faden · Massachusetts Eye And Ear Infirmary · K23 · FY2023 · DE
Dissecting temporal and spatial dynamics of immunotherapy resistance
$173,772Daniel Faden · Massachusetts Eye And Ear Infirmary · K23 · FY2022 · DE
ULK1 Inhibitor in Combination with Immune Checkpoint Blockade in PancreaticCancer
$173,764Jeffrey Paul Mackeigan · Michigan State University · R21 · FY2024 · CA
Preoperative immunotherapy in Hepatocellular Carcinoma
$173,764Gregory B. Lesinski · Emory University · R21 · FY2024 · CA
Roles of CD47 Signaling in Tumor Immunology
$173,609David D Roberts · Division Of Clinical Sciences - Nci · ZIA · FY2021 · CA
Understanding how mitotic kinases drive EMT in breast cancers
$173,579Harold I Saavedra · Ponce School Of Medicine · U54 · FY2019 · CA
Overcoming Tumor-Intrinsic Therapeutic Resistance to Immunotherapies
$173,559Lewis Zhichang Shi · University Of Alabama At Birmingham · R21 · FY2022 · CA